Compare Air Products & Chemicals, Inc. (APD) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs AstraZeneca plc — how do they compare? Air Products & Chemicals, Inc. trades at $303.03 (market cap $66.70B), while AstraZeneca plc trades at $169.1 (market cap $262.75B). The key difference: AstraZeneca plc is far larger — about 3.9× Air Products & Chemicals, Inc.'s market cap, and Air Products & Chemicals, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| APD | AZN | |
|---|---|---|
Market Cap | $66.70B | $262.75B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $209.48 |
52-Week Low | $230.42 | $137.44 |
Enterprise Value | $84.11B | $289.00B |
Dividend Yield | 2.42% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.
The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.
AstraZeneca (AZN) trades at $171.61, down 3.85% following a Phase 3 clinical trial failure for its Wainua heart drug. The stock faces bearish technical signals with support at $167 and resistance at $177. Fundamentally, the company maintains strong profitability with 17.19% net margins and robust revenue growth, reaching $58.74B in 2025. Analyst consensus remains positive with 47.5% buy ratings despite recent setbacks.
The outlook remains cautiously optimistic as AstraZeneca's core business fundamentals remain intact with improving cash flow and debt reduction. However, pipeline execution risks and clinical trial uncertainties present near-term headwinds. Long-term investors may find value at current levels given the company's strong market position and financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
